These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9359552)

  • 1. Beta-blocker prevention of proarrhythmia and proischemia: clues from CAST, CAMIAT, and EMIAT. Cardiac Arrhythmia Suppression Trial. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. European Myocardial Infarct Amiodarone Trial.
    Kennedy HL
    Am J Cardiol; 1997 Nov; 80(9):1208-11. PubMed ID: 9359552
    [No Abstract]   [Full Text] [Related]  

  • 2. Amiodarone in high-risk post-infarction patients, Lessons from EMIAT and CAMIAT. European Myocardial Infarct Amiodarone Trial and Canadian Amiodarone Myocardial Infarction Arrhythmia Trial.
    Gambhir DS
    Indian Heart J; 1996; 48(4):339-41. PubMed ID: 8908817
    [No Abstract]   [Full Text] [Related]  

  • 3. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators.
    Boutitie F; Boissel JP; Connolly SJ; Camm AJ; Cairns JA; Julian DG; Gent M; Janse MJ; Dorian P; Frangin G
    Circulation; 1999 May; 99(17):2268-75. PubMed ID: 10226092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone. European Myocardial Infarct Amiodarone Trial. Canadian Amiodarone Myocardial Infarction Trial.
    Jafri SM; Borzak S; Goldberger J; Gheorghiade M
    Prog Cardiovasc Dis; 1998; 41(1):65-70. PubMed ID: 9717860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial).
    Janse MJ; Malik M; Camm AJ; Julian DG; Frangin GA; Schwartz PJ
    Eur Heart J; 1998 Jan; 19(1):85-95. PubMed ID: 9503180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.
    Yap YG; Camm AJ
    Am J Cardiol; 1999 Nov; 84(9A):83R-89R. PubMed ID: 10568665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.
    Malik M; Camm AJ
    Lancet; 1997 Jun; 349(9067):1767-8. PubMed ID: 9193398
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
    Cairns JA; Connolly SJ; Roberts R; Gent M
    Lancet; 1997 Mar; 349(9053):675-82. PubMed ID: 9078198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What have clinical trials taught us about proarrhythmia?
    Skanes AC; Green MS
    Can J Cardiol; 1996 Apr; 12 Suppl B():20B-26B. PubMed ID: 8616725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators.
    Julian DG; Camm AJ; Frangin G; Janse MJ; Munoz A; Schwartz PJ; Simon P
    Lancet; 1997 Mar; 349(9053):667-74. PubMed ID: 9078197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease.
    Ellison KE; Gandhi G
    Drugs; 2005; 65(6):787-97. PubMed ID: 15819591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial).
    Malik M; Camm AJ; Janse MJ; Julian DG; Frangin GA; Schwartz PJ
    J Am Coll Cardiol; 2000 Apr; 35(5):1263-75. PubMed ID: 10758969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-arrhythmia therapy after myocardial infarct: preliminary results of EMIAT and CAMIAT studies].
    Kuck KH
    Z Kardiol; 1996; 85 Suppl 6():107-13. PubMed ID: 9064953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The European Myocardial Infarct Amiodarone Trial (EMIAT). EMIAT Investigators.
    Camm AJ; Julian D; Janse G; Munoz A; Schwartz P; Simon P; Frangin G
    Am J Cardiol; 1993 Nov; 72(16):95F-98F. PubMed ID: 8237837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hotline sessions at the 20th European Congress of Cardiology.
    Verheugt FW
    Eur Heart J; 1999 Jan; 20(1):7-10. PubMed ID: 10075136
    [No Abstract]   [Full Text] [Related]  

  • 18. Amiodarone and mortality in CHF and post-MI.
    Zamorski M
    J Fam Pract; 1998 Mar; 46(3):196-7. PubMed ID: 9519009
    [No Abstract]   [Full Text] [Related]  

  • 19. [Management of patients with risk of sudden death. The amiodarone example].
    Djian J
    Arch Mal Coeur Vaiss; 1994 Jan; 87(1 Spec No):67-74. PubMed ID: 7944868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bridge, but to where?
    Sweeney MO
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):584-6. PubMed ID: 12875417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.